liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Åvall-Lundqvist, Elisabeth
Alternative names
Publications (10 of 75) Show all publications
Fuglsang, K., Haldorsen, I. S., Åvall-Lundqvist, E., Lindahl, G., Roed, H., Woie, K., . . . Blaakaer, J. (2018). Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countriesSurvey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology. Acta Obstetricia et Gynecologica Scandinavica, 97(10), 1178-1184
Open this publication in new window or tab >>Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countriesSurvey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology
Show others...
2018 (English)In: Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, E-ISSN 1600-0412, Vol. 97, no 10, p. 1178-1184Article in journal (Refereed) Published
Abstract [en]

IntroductionWomen with cervical cancer in the Nordic countries are increasingly undergoing pretreatment imaging by ultrasound, magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT) or computed tomography, or sentinel lymph node procedure. The present survey reports the influence of pretreatment imaging findings on the recorded clinical International Federation of Gynecology and Obstetrics (FIGO) stage in Nordic countries and its impact on treatment planning and preferred surgical approach in cervical cancer. Material and methodsThe Nordic Society of Gynecological Oncology Surgical Subcommittee developed a questionnaire-based survey that was conducted from 1 January to 31 March 2017. All the 22 Nordic Gynecological Oncology Centers (Denmark 5, Finland 5, Iceland 1, Norway 4, and Sweden 7) were invited to participate. ResultsThe questionnaires were returned by 19 of 22 (86.3%) centers. The median number (range) of women with cervical cancer treated at each center annually was 32 (15-120). In 58% (11/19) of the centers, imaging findings were reported to influence the clinical staging. MRI in combination with PET-CT was the preferred imaging method and the results influenced treatment planning. Robotic-assisted radical hysterectomy was the preferred surgical method in 72% (13/18) of the centers. Sentinel lymph node procedure was not routinely implemented in the majority of the Nordic centers. ConclusionMore than half of the Nordic Gynecological Oncology Centers already report a clinical FIGO stage influenced by pretreatment imaging findings. The trend in preferred treatment is robotic-assisted radical hysterectomy and the sentinel lymph node procedure is gradually being introduced.

Place, publisher, year, edition, pages
WILEY, 2018
Keywords
diagnostic imaging; gynecological surgical procedure; International Federation of Gynecology and Obstetrics; neoplasm staging; Nordic Society of Gynecological Oncology; pretreatment elaboration; sentinel lymph node; uterine cervical neoplasm
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:liu:diva-151632 (URN)10.1111/aogs.13388 (DOI)000444070900005 ()29799176 (PubMedID)
Available from: 2018-09-27 Created: 2018-09-27 Last updated: 2019-04-09
Cibula, D., Poetter, R., Planchamp, F., Åvall-Lundqvist, E., Fischerova, D., Haie-Meder, C., . . . Raspollini, M. R. (2018). Correction: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (vol 472, pg 919, 2018). Virchows Archiv, 472(6), 937-938
Open this publication in new window or tab >>Correction: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (vol 472, pg 919, 2018)
Show others...
2018 (English)In: Virchows Archiv, ISSN 0945-6317, E-ISSN 1432-2307, Vol. 472, no 6, p. 937-938Article in journal (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Springer, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-149728 (URN)10.1007/s00428-018-2380-7 (DOI)000435410300006 ()29789924 (PubMedID)2-s2.0-85048484962 (Scopus ID)
Note

Correction to: Virchows Arch (2018)

 https://doi.org/10.1007/s00428-018-2362-9

Two corrections were made to the above publication following its original online publication on 4th May 2018.

Available from: 2018-07-24 Created: 2018-07-24 Last updated: 2019-04-17Bibliographically approved
Cibula, D., Poetter, R., Planchamp, F., Åvall-Lundqvist, E., Fischerova, D., Haie-Meder, C., . . . Raspollini, M. R. (2018). Correction to: Correction: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (vol 472, pg 919, 2018). Virchows Archiv, 473(3), 391-391
Open this publication in new window or tab >>Correction to: Correction: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (vol 472, pg 919, 2018)
Show others...
2018 (English)In: Virchows Archiv, ISSN 0945-6317, E-ISSN 1432-2307, Vol. 473, no 3, p. 391-391Article in journal (Refereed) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Springer, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-151499 (URN)10.1007/s00428-018-2419-9 (DOI)000443403100016 ()30043108 (PubMedID)2-s2.0-85050582265 (Scopus ID)
Note

Regrettably, the author metadata used for the previous correction (doi:  https://doi.org/10.1007/s00428-018-2380-7) contained an error in the tagging of W. Glenn McCluggage’s name; this has been corrected. No further adjustments have been made to the Correction, or the original Guideline paper (doi:  https://doi.org/10.1007/s00428-018-2362-9).

Available from: 2018-09-24 Created: 2018-09-24 Last updated: 2019-04-17Bibliographically approved
Rosenberg, P., Kjölhede, P., Staf, C., Bjurberg, M., Borgfeldt, C., Dahm-Kahler, P., . . . Hogberg, T. (2018). Data quality in the Swedish Quality Register of Gynecologic Cancer - a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncologica, 57(3), 346-353
Open this publication in new window or tab >>Data quality in the Swedish Quality Register of Gynecologic Cancer - a Swedish Gynecologic Cancer Group (SweGCG) study
Show others...
2018 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 57, no 3, p. 346-353Article in journal (Refereed) Published
Abstract [en]

Aim: The aim of this study is to evaluate the quality of data on endometrial (EC) and ovarian, fallopian tube, peritoneal, abdominal or pelvic cancers (OC) registered in the Swedish Quality Register of Gynecologic Cancer (SQRGC).Method: A random sample of 500 patients was identified in the SQRGC and their medical charts were reviewed for re-abstraction of 31 selected core variables by an independent validator. The data in the SQRGC and the re-abstracted data were compared. The data were collected from 25 hospitals evenly distributed throughout Sweden. The main outcomes were comparability, timeliness, completeness and validity. Coverage was compared with the National Cancer Register (NCR). Timeliness was defined as the speed of registration i.e. when patients were registered in the SQRGC relative to date of diagnosis. Internationally accepted coding systems for stage, grading and histologic type were used ensuring a high degree of comparability. Correlations were estimated using Pearsons correlation coefficient and Cohens kappa coefficient.Results: The completeness was 95%. The timeliness was 88-91% within 12 months of diagnosis. The median degree of agreement between re-abstracted data and data in the SQRGC was 82.1%, with a median kappa value of 0.73 for ordinate variables and a median Pearsons correlation coefficient of 0.96. The agreements for the type of surgery were 76% (95% CI 70-81%; kappa 0.49) and type of primary treatment 90% (95% CI 87-94%; kappa 0.85) in OC and in EC 88% (95% CI 84-93%; kappa 0.84). The agreements for the FIGO stage were in OC and EC 74% (95% CI 68-80%; kappa 0.69) and 87% (95% CI 82-91%; kappa 0.79), respectively.Conclusions: The data in the Swedish Quality Register for Gynecologic Cancer are of adequate quality in order to be used as a basis for research and to evaluate possible differences in treatment, lead times and treatment results.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD, 2018
National Category
Surgery
Identifiers
urn:nbn:se:liu:diva-145150 (URN)10.1080/0284186X.2017.1366048 (DOI)000423754200007 ()28828920 (PubMedID)
Note

Funding Agencies|Swedish Association of Local Authorities and Regions; Swedish Cancer Society

Available from: 2018-02-13 Created: 2018-02-13 Last updated: 2019-04-09
Dostalek, L., Åvall-Lundqvist, E., Creutzberg, C. L., Kurdiani, D., Ponce, J., Dostalkova, I. & Cibula, D. (2018). ESGO Survey on Current Practice in the Management of Cervical Cancer. International Journal of Gynecological Cancer, 28(6), 1226-1231
Open this publication in new window or tab >>ESGO Survey on Current Practice in the Management of Cervical Cancer
Show others...
2018 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 28, no 6, p. 1226-1231Article in journal (Refereed) Published
Abstract [en]

Objective The aim of this survey was to acquire an overview of the current management of cervical cancer with an emphasis on the early disease stages. Materials and Methods A hyperlink to the survey was sent to the European Society of Gynaecological Oncology Office database. The survey contained 6 groups of questions regarding the characteristics of respondents, pretreatment workup, management of the early stages of cervical cancer, adjuvant treatment, fertility-sparing treatment, and surveillance. Results In total, 566 responses were collected. The most frequent imaging method used in the workup was magnetic resonance imaging (74%), followed by computed tomography (54%) and positron emission tomography/computed tomography (25%). Conization or simple hysterectomy was a preferred procedure in stage T1a1 lymphovascular space invasion (LVSI)-positive for 79% of respondents, in stage T1a2 LVSI-negative for 58%, and in stage T1a2 LVSI-positive for 28%. Sentinel lymph node biopsy alone was reported in stage T1a1 by 17% and in stage T1b1 less than 2 cm by 9%, whereas systematic lymphadenectomy by 29% and 90% of respondents. Macrometastases, micrometastases, and isolated tumor cells in lymph nodes were considered indications for adjuvant treatment by 96%, 93%, and 68% of respondents, respectively. Neoadjuvant chemotherapy was reported by 28% and 19% of respondents in fertility-sparing and nonsparing management in stage T1b1. Over 60% of respondents recommend primary surgery for their patients with T1b2 N0 disease and 81% of them use a combination of adverse prognostic factors as indication for adjuvant radiotherapy in pN0 disease. Conclusions The results of this survey indicate considerable differences in the workup and treatment of cervical cancer in current clinical practice.

Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS, 2018
Keywords
Cervical cancer; Survey; Early stage; Staging; Treatment
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-149869 (URN)10.1097/IGC.0000000000001314 (DOI)000437455300025 ()29958236 (PubMedID)
Note

Funding Agencies|Charles University in Prague [UNCE 204065, Q28/LF1]

Available from: 2018-08-02 Created: 2018-08-02 Last updated: 2019-04-09
Salehi, S., Brandberg, Y., Åvall-Lundqvist, E., Suzuki, C., Johansson, H., Legerstam, B. & Falconer, H. (2018). Long-term quality of life after comprehensive surgical staging of high-risk endometrial cancer - results from the RASHEC trial. Acta Oncologica, 57(12), 1671-1676
Open this publication in new window or tab >>Long-term quality of life after comprehensive surgical staging of high-risk endometrial cancer - results from the RASHEC trial
Show others...
2018 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 57, no 12, p. 1671-1676Article in journal (Refereed) Published
Abstract [en]

Purpose: The health-related quality of life (HRQoL) outcomes after comprehensive surgical staging including infrarenal paraaortic lymphadenectomy in women with high-risk endometrial cancer (EC) are unknown. Our aim was to investigate the long-term HRQoL between robot-assisted laparoscopic surgery (RALS) and laparotomy (LT). Patients and Methods: A total of 120 women with high-risk stage I-II EC were randomised to RALS or LT for hysterectomy, bilateral salpingoophorectomy, pelvic and infrarenal paraaortic lymphadenectomy in the previously reported Robot-Assisted Surgery for High-Risk Endometrial Cancer trial. The HRQoL was measured with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-30) and its supplementary questionnaire module for endometrial cancer (QLQ-EN24) questionnaire. Women were assessed before and 12 months after surgery. In addition, the EuroQol Eq5D non-disease specific questionnaire was used for descriptive analysis. Results: There was no difference in the functional scales (including global health status) in the intention to treat analysis, though LT conferred a small clinically important difference (CID) over RALS in cognitive functioning albeit not statistically significant -6 (95% CI-14 to 0, p = .06). LT conferred a significantly better outcome for the nausea and vomiting item though it did not reach a CID, 4 (95% CI 1 to 7, p = .01). In the EORTC-QLQ/QLQ-EN24, no significant differences were observed. Eq5D-3L questionnaire demonstrated a higher proportion of women reporting any extent of mobility impairment 12 months after surgery in the LT arm (p = .03). Conclusion: Overall, laparotomy and robot-assisted surgery conferred similar HRQoL 12 months after comprehensive staging for high-risk EC.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-153679 (URN)10.1080/0284186X.2018.1521987 (DOI)000453867800011 ()30289327 (PubMedID)
Note

Funding Agencies|Radiumhemmets Forskningsfonder

Available from: 2019-01-07 Created: 2019-01-07 Last updated: 2019-04-09
Hjerpe, E., Staf, C., Dahm-Kahler, P., Stalberg, K., Bjurberg, M., Holmberg, E., . . . Åvall-Lundqvist, E. (2018). Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncologica, 57(3), 331-337
Open this publication in new window or tab >>Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study
Show others...
2018 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 57, no 3, p. 331-337Article in journal (Refereed) Published
Abstract [en]

Background: The International Federation of Gynecology and Obstetrics (FIGO) ovarian cancer staging system includes no sub-stage for lymph nodes (LN) as only distant disease manifestation. We explore the prognostic implication of LN as only stage IV classifier in serous ovarian cancer.Method: This is a nation-wide, population-based study on 551 women with serous stage IV cancers diagnosed between 2009-2014. We compare overall survival (OS) in women with LN as only distant metastatic site to those with pleural metastases only and to patients with other/multiple stage IV manifestations. Cox regression models were used for uni- and multivariable estimations.Results: Of 551stage IV cases, distant metastatic site was registered in 433. Median OS for women with LN (n=51) was 41.4 months, compared to 25.2 and 26.8 months for patients with pleural (n=195) or other/multiple (n=187) distant metastases (p=.0007). The corresponding five-year survival rates were 32, 11 and 22%, respectively. Multivariable analyzes confirmed shorter survival for women with pleural (HR 2.99, p=.001) or other/multiple distant sites (HR 2.67, p=.007), as compared to LN cases. LN only patients lived 9.1 months longer after primary than after interval surgery, but this difference was not significant (p=.245).Conclusion: Women with stage IV serous ovarian cancer having lymph nodes as only distant metastatic site live longer than other stage IV patients.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-145149 (URN)10.1080/0284186X.2017.1400691 (DOI)000423754200005 ()29130381 (PubMedID)
Note

Funding Agencies|Swedish Cancer Society; Cancer Research Funds of Radiumhemmet

Available from: 2018-02-13 Created: 2018-02-13 Last updated: 2019-04-09
King, M. T., Stockler, M. R., OConnell, R. L., Buizen, L., Joly, F., Lanceley, A., . . . Friedlander, M. L. (2018). Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research, 27(1), 59-74
Open this publication in new window or tab >>Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Show others...
2018 (English)In: Quality of Life Research, ISSN 0962-9343, E-ISSN 1573-2649, Vol. 27, no 1, p. 59-74Article in journal (Refereed) Published
Abstract [en]

Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM), the Measure of Ovarian Symptoms and Treatment concerns (MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items), and document recurrent ovarian cancer (ROC) symptom burden and benefit. GCIG-SBS Stage 2 recruited patients with platinum-resistant/refractory ROC (PRR-ROC) or potentially platinum-sensitive ROC with aeamp;lt;yenamp;gt; 3 lines of prior chemotherapy (PPS-ROC aeamp;lt;yenamp;gt; 3). Patients completed MOSTv1, QLQ-C30, QLQ-OV28, and FACT-O/FOSI at baseline and before cycle 3 of chemotherapy (pre-C3), and global assessments of change (MOST-Change) pre-C3. Clinicians rated patients cancer-related symptoms, performance status, and adverse events. Convergent and divergent validity (Spearmans correlations), discriminative validity (effect sizes between groups classified by clinician-rated characteristics), and responsiveness (paired t tests in patients expected to experience clinically meaningful change) were assessed. Of 948 recruits, 903 completed PROMs at baseline and 685 pre-C3. Baseline symptom burden was substantial for PRR-ROC and PPS-ROC aeamp;lt;yenamp;gt; 3. MOSTv2 has 24 items and five multi-item scales: abdominal symptoms (MOST-Abdo), disease or treatment-related symptoms (MOST-DorT), chemotherapy-related symptoms (MOST-Chemo), psychological symptoms (MOST-Psych), and MOST-Well-being. Correlations confirmed concurrent and divergent validity. Discriminative validity was confirmed by effect sizes that conformed with a priori hypotheses. MOST-Abdo was responsive to improvements in abdominal symptoms and MOST-Chemo detected the adverse effects of chemotherapy. The MOSTv2 validly quantifies patient-reported symptom burden, adverse effects, and symptom benefit in ROC, and as such is fit-for-purpose for clinical trials of palliative chemotherapy in ROC. Further research is required to assess test-retest reliability.

Place, publisher, year, edition, pages
SPRINGER, 2018
Keywords
Ovarian cancer; Recurrent ovarian cancer; Platinum sensitive; Platinum resistant; Platinum refractory; Symptom burden; Symptom benefit; Magnitude of clinical benefit; Net health benefit; Patient-reported outcome; PRO; Patient-reported outcome measure; PROM; Quality of life; QOL; Health-related quality of life; HRQOL; HRQL
National Category
Neurology
Identifiers
urn:nbn:se:liu:diva-144892 (URN)10.1007/s11136-017-1729-8 (DOI)000422793600007 ()29248998 (PubMedID)
Note

Funding Agencies|NHMRC [1063012, 570,893]; Target Ovarian Cancer [UCL-P001AL]; Cancer Research UK [C444/A15953]; UCL Cancer Trials Centre [C444/A15953]; Australian Government through Cancer Australia; NHMRC; Department of Health

Available from: 2018-02-09 Created: 2018-02-09 Last updated: 2019-04-09
Cibula, D., Poetter, R., Planchamp, F., Åvall-Lundqvist, E., Fischerova, D., Meder, C. H., . . . Raspollini, M. R. (2018). The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. International Journal of Gynecological Cancer, 28(4), 641-655
Open this publication in new window or tab >>The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer
Show others...
2018 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 28, no 4, p. 641-655Article in journal (Refereed) Published
Abstract [en]

Background Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. Objective The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. Methods The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. Results The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.

Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS, 2018
Keywords
Cervical cancer; Guidelines; Management; Staging; Follow-up
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-147914 (URN)10.1097/IGC.0000000000001216 (DOI)000431413200001 ()29688967 (PubMedID)
Note

Funding Agencies|Institut National du Cancer (France)

Available from: 2018-05-23 Created: 2018-05-23 Last updated: 2019-04-09
Cibula, D., Poetter, R., Planchamp, F., Åvall-Lundqvist, E., Fischerova, D., Meder, C. H., . . . Raspollini, M. R. (2018). The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiotherapy and Oncology, 127(3), 404-416
Open this publication in new window or tab >>The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer
Show others...
2018 (English)In: Radiotherapy and Oncology, ISSN 0167-8140, E-ISSN 1879-0887, Vol. 127, no 3, p. 404-416Article in journal (Refereed) Published
Abstract [en]

Background: Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. Objective: The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. Methods: The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. Results: The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined. (C) 2018 European Society for Gynaecological Oncology, European Society for Radiotherapy and Oncology, and the European Society of Pathology. Published by Elsevier B.V. All rights reserved.

Place, publisher, year, edition, pages
ELSEVIER IRELAND LTD, 2018
Keywords
Cervical cancer; Guidelines; Management; Staging; Follow-up
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-149721 (URN)10.1016/j.radonc.2018.03.003 (DOI)000437110000011 ()29728273 (PubMedID)
Note

Funding Agencies|Institut National du Cancer (France)

Available from: 2018-07-24 Created: 2018-07-24 Last updated: 2019-04-09
Organisations

Search in DiVA

Show all publications